Trimethosel

Quick links to important sections

Trimethosel

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trimethosel

Quick Facts

Property Description
Active ingredients Trimethoprim, Sulfadimidine (Sulfamethazine)
Form Oral solution, Water-soluble powder, Injection solution, Suspension
Pharmacological class Potentiated Sulfonamide (Antimicrobial Agent)
General purpose Counteracting bacterial infections
Origin Synthetic, Fixed-dose Combination

What Type of Antimicrobial Agent is Trimethosel?

Trimethosel is primarily defined as a synthetic, potentiated sulfonamide antimicrobial agent, distinguished by its nature as a fixed-dose combination product. This classification places it within the general category of antifolate antibiotics, specifically used in veterinary medicine.

The designation as a potentiated sulfonamide signifies a deliberate pairing intended to achieve a synergistic action against susceptible pathogens. The general purpose of this broad-spectrum agent is to provide a highly effective solution for controlling a wide range of bacterial infections across its intended patient groups, which typically include livestock such as calves, swine, goats, and poultry. This combination is clinically recognized for its efficacy against infections affecting the respiratory, gastrointestinal, and urogenital systems in target species.

Composition: Trimethoprim and Sulfadimidine Combination

The core composition of Trimethosel relies on the two key active ingredients: Trimethoprim and Sulfadimidine (or Sulfamethazine). The formulation is effective because these two agents target a sequential metabolic process. This synergistic combination is also referred to conceptually as Co-trimazine in some veterinary contexts.

This combination works through a principle known as sequential blockade. Trimethoprim, a diaminopyrimidine inhibitor, acts on one step of the metabolic chain, while the sulfonamide, Sulfadimidine, acts on an earlier step in the folic acid synthesis pathway. Inhibiting two consecutive steps in the bacterial metabolism yields a robust bactericidal action—meaning the drug actively kills the bacteria.

Available Preparations

Trimethosel is a synthetic medicine manufactured in several dosage forms to accommodate various clinical needs and routes of administration, including oral and parenteral methods.

The common pharmaceutical preparations include an oral solution, a water-soluble powder designed for mixing, an injection solution for systemic use, and a suspension. The availability of these preparations ensures flexibility, particularly in treating infections across varied patient populations, such as treating respiratory infections in swine or calf scours.

What side effects are possible with Trimethosel?

Possible side effects and safety information

The safety profile of Trimethosel (Trimethoprim/Sulfadimidine) is organized in regulatory documents based on the body systems affected and the frequency of occurrence. These classifications separate typically expected effects from rare but clinically significant adverse reactions, providing a framework for risk understanding.

Component Description
Key adverse reaction categories Gastrointestinal disturbances, Hematologic effects, Dermatological reactions, Hypersensitivity, Hepatic and Renal toxicity.
Frequency classification Common (Gastrointestinal disturbances, mild skin reactions); Rare (Severe cutaneous reactions, severe hematologic changes, neurological effects).
System-organ classes involved Blood and Lymphatic System Disorders, Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders, Hepatobiliary Disorders, Renal and Urinary Disorders, Immune System Disorders, Nervous System Disorders.

Serious adverse reactions are specifically documented in regulatory labeling. These include potentially fatal conditions such as Aplastic Anemia, Agranulocytosis, Severe Cutaneous Adverse Reactions (SCARs), Anaphylaxis, and Acute Renal Failure due to crystalluria.

Specific safety considerations address vulnerable individuals. The medicine is contraindicated in cases of known Sulfonamide or Trimethoprim Hypersensitivity, severe liver damage, severe renal failure, or pre-existing blood dyscrasias. Furthermore, individuals with folate deficiency have a heightened risk of developing hematologic side effects. Exposure patterns noted in regulatory texts associate folate deficiency-related effects with prolonged or high-dose administration, while acute hypersensitivity reactions may occur early in treatment.

This official safety documentation allows for a proportional understanding of the potential outcomes, ranging from the common, expected effects to the rare, serious risks.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented manifestations and required actions in the event of an overdose of Trimethosel (a potentiated sulfonamide combination), based exclusively on government regulatory sources.

Overdose can present with acute toxic manifestations following a single excessive dose or with chronic toxicity from prolonged, high-dose exposure.


Documented Overdose Presentations

Classification Manifestations Listed in Regulatory Documents
Acute Toxic Signs Collapse, blindness, muscle weakness, ataxia, anaphylaxis, severe vomiting, confusion.
Chronic/High-Dose Signs of serious blood disorders, including anemia, pancytopenia, and bone marrow depression.

Required Emergency Actions

Urgent medical attention must be sought immediately upon observing any signs of an acute toxic manifestation (e.g., collapse, loss of consciousness) or early indicators of a serious adverse reaction (e.g., fever, purpura, severe rash). Regulators mandate the immediate discontinuation of the drug at the first appearance of such signs.

Management is generally symptomatic and supportive. For chronic toxicity affecting the blood, specific steps required include obtaining complete blood counts (CBCs) and administering folinic acid (leucovorin) to counteract the documented folate deficiency effects.

Therapeutic Uses of Trimethosel

What Trimethosel Treats: Main Uses and Benefits

Trimethosel (Trimethoprim/Sulfadimidine) is a potentiated sulfonamide combination commonly used to help with infections caused by susceptible bacteria and some protozoa across major organ systems in veterinary medicine. Its use is considered relevant in clinical settings marked by increased discomfort or tension, and may be part of symptomatic management when systemic burden is heightened. The combination is applied in addressing conditions where systemic antibacterial action against susceptible organisms is needed, including acute infections across multiple body systems.

The medication is commonly used across conditions presenting with acute episodes involving the respiratory, gastrointestinal, and urogenital systems, as well as systemic illnesses and localized infections such as abscesses.

“Applied in scenarios where additional management of discomfort is required, Trimethosel assists with maintaining functional stability during episodes of heightened symptoms.”

Quick Fact: Relief for Acute Distress
Common Symptoms Addressed Fever, severe diarrhea (scours), and labored breathing.
Supportive Symptom Effect Supports stability during periods of heightened systemic and functional stress.
Common Use Context Applied in settings where short-term symptomatic assistance is needed for acute episodes.

Eligibility and Restrictions for Use

Who Can and Cannot Use Trimethosel?

The official regulatory profile for Trimethosel defines its use exclusively as a veterinary antimicrobial agent for specific livestock. Consequently, the medicine is contraindicated for human use under all circumstances.

Eligibility is strictly limited to the approved target species, which typically include calves, swine, goats, and poultry. Use in any non-target species is not recommended or not established by regulatory authorities.

Absolute Contraindications

Absolute non-eligibility is mandated for animals with a known hypersensitivity to either Trimethoprim or Sulfadimidine (Sulfonamides). Furthermore, the medicine is prohibited in individuals diagnosed with severe renal failure, severe hepatic impairment, or existing hematological disorders (such as severe anemia).

Conditional Use and Restrictions

Use is restricted or not recommended for very young, neonatal animals due to undeveloped metabolic functions. For animals intended for food production, eligibility is conditional upon strict adherence to mandated drug withdrawal periods to prevent tissue residue. Use in pregnant or breeding animals is also classified as restricted.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Trimethosel (Trimethoprim/Sulfadimidine) as established in government regulatory prescribing information.

Interaction Scope

Scope Element Documented Regulatory Information
Medicinal product categories with documented interactions Antifolate antagonists, ACE Inhibitors/ARBs, Potassium-Sparing Diuretics, Oral Hypoglycemics (CYP2C8/CYP2C9 substrates), Anticoagulants, and Immunosuppressants.
Specific interacting medicines (if explicitly listed) Dofetilide, Methenamine, Phenytoin, Warfarin, Pyrimethamine, Digoxin, Amantadine, and Cyclosporine.
Mechanistic basis of interactions (only if stated in label) Inhibition of hepatic metabolism, OCT2 substrate/inhibitor interactions, and Pharmacodynamic (PD) synergy (e.g., additive hyperkalemia).
Interaction-related restrictions Contraindicated for co-administration with Dofetilide and Methenamine. Potentiating the anticoagulant effect of Warfarin requires close monitoring.
Population-specific interaction notes (if applicable) Increased incidence of thrombocytopenia with purpura in elderly patients concurrently receiving Diuretics. Risk of increased Digoxin blood levels is also noted in elderly patients.

The official regulatory documents establish the interaction profile through two mechanisms: the inhibition of clearance pathways for co-administered drugs (Pharmacokinetic) and the reinforcement of specific physiological effects, such as hyperkalemia (Pharmacodynamic). These documented interaction patterns necessitate specific monitoring procedures, particularly concerning plasma concentrations of narrow-therapeutic-index drugs like Phenytoin and Warfarin. The profile also defines absolute prohibitions on co-administration with certain agents, classifying those combinations as formally contraindicated in official labeling.

Mechanism of Action

The mechanism of Trimethosel is defined by its dual-level effect on bacterial metabolism, resulting in the killing of susceptible bacterial pathogens.


Selective Dual-Enzyme Inhibition

Trimethosel acts by inhibiting two key enzymes essential for the survival of bacterial cells: Dihydropteroate Synthase ( DHPS) and Dihydrofolate Reductase ( DHFR). This process is highly selective, as the active ingredient Trimethoprim binds to the bacterial DHFR enzyme with an affinity significantly greater than its binding to the analogous enzyme in the host animal. The targeted inhibition of these enzymes initiates an acute metabolic deficiency within the pathogen.


Synergistic Sequential Pathway Blockade

The two agents are combined to create a sequential blockade in the bacterial folic acid synthesis pathway. Sulfadimidine inhibits the initial step, and Trimethoprim inhibits the subsequent step, creating a synergistic effect. This cascade completely halts the production of active Tetrahydrofolate ( THF), which is vital for synthesizing DNA and RNA precursors. The resulting lack of nucleic acids rapidly kills the bacterial cell, driving the action from growth-arresting to a bactericidal effect. The core physiological consequence of the drug's action is the death of susceptible bacterial populations.

Dosage and Administration Information

Trimethosel (a combination of Trimethoprim and a sulfonamide) is administered according to a precise dosage protocol, which establishes the standardized approach to use. The medicine is available in multiple forms to support varied administration routes, including Oral preparations (solution, powder, bolus), and Parenteral preparations for injection. The administration route is determined by the target species and clinical necessity.

Oral preparations are commonly mixed into drinking water or feed, or given directly as a drench or suspension. Systemic administration via injection uses the Intramuscular (IM) or Slow Intravenous (IV) routes in livestock, or the Subcutaneous (SC) route in smaller animals.

Dosing and Duration

The standard administration schedule requires a daily combined dose of 15 mg of active ingredients per kg of body weight, though some official regimens permit up to 30 mg/kg combined actives. This dose is typically administered once daily for injections, or twice daily for certain oral suspensions. Preparation is essential: oral powders must be fully incorporated into the liquid, and the injectable solution should be warmed before slow IV administration.

The duration of the course is typically limited to 5 to 7 days total. Treatment must be continued for 48 hours after the visible symptoms resolve, but should not exceed the maximum total prescribed duration. Specific use rules apply, such as restricting certain oral forms for pre-ruminant animals only.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Trimethosel

Evidence for Use in Lower Respiratory Tract Infections (LRTIs)

Research explored the Trimethosel combination in the context of susceptible bacterial infections of the lower respiratory system, primarily involving Randomized Controlled Field Trials (RCTs). These types of studies are used in research exploring how symptoms change over time and included specific patient populations, mainly horses. In these trials, the research examined outcomes related to changes in physical discomfort and the rate of bacteriological eradication (elimination of the target organism), which is an outcome related to systemic or functional imbalance. The studies report how symptoms evolved in the observed populations over defined time intervals. Comparative research was evaluated in trials against either an inactive substance (placebo) or active comparator treatments.


Evidence for Use in Acute Gastrointestinal and Systemic Bacterial Infections

Research explored broad acute bacterial conditions, including conditions associated with acute or disruptive episodes like scours and infections of the gastrointestinal and urogenital systems, in a broad range of livestock species including calves, pigs, and goats. The evidence includes various Field Efficacy Studies and foundational Pharmacokinetic (PK) research. Studies explored short-term outcomes related to systemic or functional imbalance, such as the resolution of fever and diarrhea, and assessed the success rates observed in the treatment period. PK research contributes to the broader evidence landscape regarding how the active ingredients are absorbed and processed by the body in these different species.


Research Gaps and Limitations

The existing evidence is limited regarding the long-term patterns following treatment, as follow-up durations were typically short. Long-term outcomes are not fully established. A key limitation is the variability in drug ratio achieved in the bloodstream of different animal species; data show patterns related to inconsistent achievement of the intended drug ratio across species. Furthermore, research was observed in some studies to have less activity when used in infections involving a significant amount of pus or tissue debris, indicating a limiting factor in certain clinical situations. The literature also highlights that data show patterns related to increasing bacterial resistance, an area where research is ongoing.

Key Studies & References

  1. EQUISUL-SDT® (Sulfadiazine/Trimethoprim) Oral Suspension - FDA Approved NADA # 141-360
  2. Sulfonamides and Sulfonamide Combinations Use in Animals - Merck Veterinary Manual (General Information and Indications)
  3. Optimized dosing regimens for the combinations of sulphonamides and trimethoprim in veterinary medicine (SulTAn) - Research Project (Discussing research gaps and PK variability)

Frequently Asked Questions (FAQ)

Common questions about Trimethosel (FAQ)

Q: Can older adults (seniors) safely take Trimethosel?

A: Official documents note that certain risks may be increased for older individuals (seniors) within the target species. For example, when the medicine is used alongside certain diuretics (water pills), there may be an increased risk of developing a specific type of bleeding disorder. Additionally, older patients have been noted to have an increased risk of elevated blood levels of certain co-administered drugs like digoxin.

Q: Is Trimethosel approved for use in children?

A: Trimethosel is officially labeled and contraindicated for human use under all circumstances, as it is strictly a veterinary antimicrobial agent intended for specific livestock. For the approved species, use is generally restricted or not recommended for very young, neonatal animals due to their undeveloped metabolic functions.

Q: Can I take Trimethosel if I have kidney problems?

A: According to the official product information, the medicine is prohibited for use in individuals—or animals—with severe renal failure (severe kidney damage). Use may also be restricted in cases of less severe kidney impairment where the clearance of the drug from the body may be reduced. These restrictions help manage the risk of side effects related to reduced drug processing.

Q: What if I have liver disease, is Trimethosel still an option?

A: Regulatory documentation states that Trimethosel is contraindicated (prohibited) for use in individuals or animals diagnosed with severe liver damage or severe hepatic impairment. This restriction exists because the liver is essential for processing and clearing the drug from the body.

Q: What are the signs of a severe allergic reaction to Trimethosel?

A: Official documentation notes that severe allergic reactions, such as anaphylaxis and severe cutaneous reactions (SCARs), are possible but rare. Signs that may precede these life-threatening reactions can include high fever, severe headache, inflammation of the mouth (stomatitis), eye inflammation (conjunctivitis), and persistent runny nose (rhinitis).

Q: Are there any known long-term side effects of Trimethosel?

A: Official documentation indicates that research is limited regarding the long-term patterns following treatment, as follow-up durations in clinical research were typically short. Known effects such as certain serious blood-related changes are associated with prolonged or high-dose administration. The drug's official labeling does not define established long-term use patterns.

Q: If I have a history of heart issues, can I take Trimethosel?

A: Official documentation for this medicine notes a risk of interactions with specific prescription drugs often used for heart and blood pressure conditions, such as ACE Inhibitors and Potassium-Sparing Diuretics. When combined, there is a risk of additive hyperkalemia (abnormally high potassium levels). No general restriction is given regarding a history of heart issues alone.

Q: Is Trimethosel the same kind of medicine as [similar drug name]?

A: Trimethosel is officially classified as a synthetic, potentiated sulfonamide antimicrobial agent. This classification defines it as a fixed-dose combination of two active ingredients: Trimethoprim and a sulfonamide (Sulfadimidine). It is structurally related to other antimicrobial combinations that use similar ingredients, but it is categorized as its own specific combination product.

Q: Can Trimethosel cause hair loss?

A: Official adverse reaction reports include hair loss as a documented side effect for this class of medicine, although its overall frequency of occurrence is not precisely known. This type of reaction is typically listed under dermatological (skin-related) side effects.

Q: Is it okay to drink alcohol while taking Trimethosel?

A: Although the official product is for veterinary use, information regarding the active ingredient class suggests that using alcohol may lead to adverse effects, which are described in the regulatory documents. These effects can include nausea, vomiting, flushing, or a fast heartbeat (a disulfiram-like reaction) in humans.

Q: Are there any foods or supplements I should avoid with Trimethosel?

A: Official labeling generally states that the drug does not have specific restrictions on taking it with food, meaning it may be given with or without food. Official administration details provided by the prescribing professional will define any necessary use restrictions.

Q: Can Trimethosel affect my sleep?

A: Official adverse event listings for the components of Trimethosel include both drowsiness and trouble sleeping (insomnia) as reported side effects. While drowsiness is infrequent, the incidence of other sleep disturbances is generally categorized as unknown based on available reporting data.

Q: Is Trimethosel known to cause weight gain or loss?

A: Official adverse event listings for the drug components include weight loss and decreased appetite (anorexia) in human data, though the frequency is unknown. In animal studies, it has been observed that treated animals sometimes gained less weight over the treatment period compared to untreated animals.

Q: How long can a person stay on Trimethosel?

A: The product is contraindicated (prohibited) for human use and is not to be used by people. For the approved veterinary species, the typical course is limited to 5 to 7 days total. Official data on the safety and consequences of using the drug for periods longer than a typical course are limited.

Q: Does Trimethosel have a risk of dependence or addiction?

A: Trimethosel is classified by health authorities as an Antibacterial for Systemic Use. Due to its classification as an antibacterial agent, it is not listed as a medicine with known risk of dependence or addiction.

Q: Is there a generic version of Trimethosel available?

A: The combination of the two active ingredients, Sulfadimidine and Trimethoprim, is widely available internationally under various brand and generic names. Therefore, while 'Trimethosel' is one specific brand, the same active ingredient combination is available from multiple manufacturers.

Q: What is the difference between Trimethosel and a placebo in studies?

A: Regulatory-reviewed studies have compared the medicine against a placebo, which is an inactive substance used for comparison. These studies reported that the drug was associated with a significantly higher clinical response rate and a lower rate of patient withdrawal due to lack of effect in the treated groups.

Q: Do I need to take Trimethosel with food?

A: Official labeling states the drug may be given with or without food. Administration conditions are defined in the official labeling and by the prescribing professional.

Q: Is Trimethosel a controlled substance?

A: The drug is an Antibacterial for Systemic Use and is not classified as a controlled substance by major regulatory bodies.

Q: Can pregnant women use Trimethosel?

A: The product is contraindicated (prohibited) for human use under all circumstances. For the approved species, use is restricted or not recommended in pregnant or breeding animals due to potential risks to the developing fetus or reproductive capacity.

Q: Is it safe to breastfeed while on Trimethosel?

A: The product is contraindicated for human use. For the approved target species, the drug is generally restricted or not recommended for use in lactating animals because the drug's components are known to be excreted into the milk.

Q: Can taking Trimethosel cause changes in mood?

A: Official adverse event listings for the components of Trimethosel include mood-related changes as possible side effects. These include feelings of depression, discouragement, feeling sad or empty, and a lack of feeling or emotion, although the frequency of these effects is generally categorized as unknown.

Q: Is Trimethosel used for anything other than its main purpose?

A: The product is specifically approved for bacterial infections of the respiratory, gastrointestinal, and urogenital systems in target species. However, similar formulations in human medicine have been studied or used for other purposes outside of the primary label, such as for certain skin conditions.

Q: Can I stop taking Trimethosel suddenly?

A: The official product documentation states the required treatment duration often extends for 48 hours after visible symptoms resolve and requires completing the full course. This protocol is necessary to ensure the complete eradication of the bacterial infection and to help prevent the development of antibiotic resistance. The medicine itself is not associated with physical withdrawal symptoms upon cessation.

Q: Does Trimethosel interact with herbal supplements like St. John's Wort?

A: Regulatory information for related formulations indicates that the herbal supplement St. John's Wort may interfere with the metabolism of the active ingredients. This interference could potentially reduce the blood levels of trimethoprim, making the antibiotic component less effective.

Q: Is there any difference between taking the tablet and the liquid form of Trimethosel?

A: Official documents define different administration methods and schedules for different forms. For example, injections may be given once daily, while certain oral suspensions are given twice daily. Research also shows that different forms can have varying absorption characteristics in the body.

Q: Can I take other prescription medications with Trimethosel?

A: Regulatory documents list numerous drug categories with documented interaction risks, including ACE Inhibitors/ARBs, Anticoagulants (like Warfarin), and specific medicines like Digoxin and Phenytoin. Co-administration is formally contraindicated (prohibited) with Dofetilide and Methenamine.

Q: What should I do if the side effects of Trimethosel are too bothersome?

A: The official documentation states that severe side effects, or a lack of improvement in the condition, warrant contact with a prescribing professional. This contact should also occur if the animal’s condition worsens or does not improve with the prescribed treatment.

Q: Is a doctor's prescription required for Trimethosel?

A: Trimethosel is classified as an FDA-approved veterinary medication for specified species. It is legally classified as a prescription drug and is not available over-the-counter.

Q: Are there any specific laboratory tests required before or during treatment with Trimethosel?

A: Regulatory text advises that close monitoring is necessary when the drug is co-administered with certain narrow-therapeutic-index drugs (like Phenytoin). Blood tests, such as a Complete Blood Count, are noted in regulatory information as a consideration during prolonged therapy or higher-dose administration to evaluate effects on blood cell counts.

Q: What is the general success rate mentioned in clinical trials for Trimethosel?

A: Regulatory-reviewed studies for specific conditions report varying outcomes. For example, in studies involving horses with lower respiratory infections, a positive clinical response was reported in approximately 58% of the animals that received the treatment.

Q: Can I take a flu shot or other vaccines while on Trimethosel?

A: Regulatory information for the components indicates that they may reduce the activity of certain live vaccines, such as the live typhoid vaccine. It is noted that the vaccine may not be fully effective until a few days after antibiotic therapy is complete.

Q: Is Trimethosel associated with any vision changes?

A: Adverse event reports for the drug class include documented but uncommon visual disturbances. These can include changes in vision and inflammation of the eye (such as conjunctivitis).

Q: What should I do if I accidentally take too much Trimethosel?

A: The official product documentation states that a suspected overdose warrants immediate contact with a prescribing professional. Overdose symptoms may vary but could include adverse effects related to the central nervous system, gastrointestinal system, or blood disorders.

Q: Why do some people feel fatigued when starting Trimethosel?

A: Official adverse event listings for this medicine include fatigue or weakness as documented side effects, though the specific incidence is generally not known. The feeling of tiredness may also be related to the underlying infection being treated.

How should Trimethosel be stored and disposed of?

Storage and Disposal Requirements

Official labeling defines specific conditions for storing and disposing of the medicine containing trimethoprim and sulfadimidine.

Required Storage Conditions

The product must be stored at Controlled Room Temperature, generally defined as 20 C to 25 C (68 F to 77 F). Storage must ensure protection from both light and moisture. Liquid formulations should not be allowed to freeze. The medicine must be kept in its original container, tightly closed, and stored out of the sight and reach of children.

Stability and Disposal

For liquid preparations, the stability time is limited after opening; for instance, diluted solutions may need to be discarded if not used within 24 hours. Expired or unused product must be disposed of in accordance with local regulatory requirements. It is officially mandated that the product or its waste does not contaminate waterways.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trimethosel found in:

A-Z Index: